[PRTK] Paratek Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 14.2 Change: 0.9 (6.77%)
Ext. hours: Change: 0 (0%)

chart PRTK

Refresh chart

Strongest Trends Summary For PRTK

PRTK is in the medium-term down -28% in 2 months and down -35% below S&P in 4 months. In the long-term down -83% below S&P in 2 years and down -97% below S&P in 14 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines to save lives and alleviate suffering. Its lead product candidate, omadacycline, is a tetracycline-derived, broad-spectrum antibiotic being developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with The Food and Drug Administration (FDA) for the Phase III trials planned in ABSSSI and CABP. Its other product candidate, WC 3035 (sarecycline), is a new tetracycline-derived compound, with dual narrow-spectrum antibacterial and potent anti-inflammatory activity for the treatment of acne and rosacea in the community setting. The company has licensed rights of WC 3035 to Actavis, which has completed Phase II clinical tr

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-27.34% ROE-32.12% ROI
Current Ratio12.91 Quick Ratio Long Term Debt/Equity Debt Ratio0.09
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities20 K Cash From Investing Activities-140 K Cash From Operating Activities-3.23 M Gross Profit
Net Profit-10.63 M Operating Profit-10.63 M Total Assets99.7 M Total Current Assets94.04 M
Total Current Liabilities7.28 M Total Debt1.42 M Total Liabilities14.85 M Total Revenue
Technical Data
High 52 week11.9 Low 52 week4.52 Last close4.55 Last change0.66%
RSI27.35 Average true range0.33 Beta0.66 Volume179.86 K
Simple moving average 20 days-13.43% Simple moving average 50 days-19.95% Simple moving average 200 days-38.42%
Performance Data
Performance Week-14.31% Performance Month-18.31% Performance Quart-37.07% Performance Half-33.58%
Performance Year-60.94% Performance Year-to-date-11.31% Volatility daily3.64% Volatility weekly8.14%
Volatility monthly16.68% Volatility yearly57.8% Relative Volume260.49% Average Volume298.58 K
New High New Low


2019-06-25 16:01:00 | Paratek Pharmaceuticals Promotes Evan Loh, M.D. to Chief Executive Officer; Michael Bigham to Assume Role of Executive Chairman

2019-06-20 11:48:50 | Biotech companies dominate fastest-growing public companies list again

2019-06-20 11:13:00 | Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019

2019-06-07 09:27:00 | Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Innovative Therapies to Fight Drug-Resistant Infections

2019-05-09 00:06:52 | Edited Transcript of PRTK earnings conference call or presentation 8-May-19 8:30pm GMT

2019-05-08 17:25:09 | Paratek Pharmaceuticals PRTK Reports Q1 Loss, Tops Revenue Estimates

2019-05-08 16:25:43 | Paratek: 1Q Earnings Snapshot

2019-05-08 16:05:00 | Paratek’s NUZYRA™ omadacycline Generates Net Sales of $1.3 Million in the First Eight Weeks on the U.S. Market

2019-05-01 10:32:02 | Analysts Estimate Paratek Pharmaceuticals PRTK to Report a Decline in Earnings: What to Look Out for

2019-04-30 16:05:00 | Paratek Pharmaceuticals to Report First Quarter 2019 Financial Results on May 8, 2019

2019-04-20 09:27:23 | Should You Be Pleased About The CEO Pay At Paratek Pharmaceuticals, Inc.'s NASDAQ:PRTK

2019-04-15 16:30:00 | Paratek Pharmaceuticals Broadens Clinical Profile of NUZYRA™ Omadacycline with New ECCMID 2019 Data Presentations

2019-04-12 10:08:00 | Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases ECCMID

2019-04-04 08:30:00 | Paratek Pharmaceuticals Presenting New Data from NUZYRA™ Omadacycline Development Program at ECCMID 2019

2019-04-01 09:05:00 | Paratek Pharmaceuticals Receives American Chemical Society 2019 Heroes of Chemistry Award

2019-04-01 08:10:00 | Market Trends Toward New Normal in Verizon Communications, Digital Turbine, Vericel, Capstead Mortgage, Paratek Pharmaceuticals, and CryoPort — Emerging Consolidated Expectations, Analyst Ratings

2019-03-28 08:00:00 | Paratek Pharmaceuticals to Present at the 2019 H.C Wainwright Global Life Sciences Conference

2019-03-20 13:35:44 | Seth Klarman's Small Caps: Worth a Look?

2019-03-18 08:00:00 | Paratek Pharmaceuticals Announces Management Change

2019-03-07 12:47:33 | What Should Investors Know About Paratek Pharmaceuticals, Inc.’s NASDAQ:PRTK Future?

2019-03-01 16:30:00 | Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635c4

2019-03-01 08:00:00 | Paratek Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference

2019-02-28 02:19:29 | Edited Transcript of PRTK earnings conference call or presentation 27-Feb-19 9:30pm GMT

2019-02-27 21:08:07 | Paratek Pharmaceuticals Inc PRTK Q4 2018 Earnings Conference Call Transcript

2019-02-27 16:01:00 | Paratek Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

2019-02-20 10:31:03 | Will Paratek Pharmaceuticals PRTK Report Negative Earnings Next Week? What You Should Know

2019-02-14 16:05:00 | Paratek Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference

2019-02-13 16:05:00 | Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results on February 27, 2019

2019-02-06 17:05:00 | New England Journal of Medicine Publishes Results from Pivotal Phase 3 Studies of Paratek’s NUZYRA™ Omadacycline For Pneumonia and Skin Infections

2019-02-06 08:23:47 | The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering

2019-02-05 16:05:00 | Paratek Pharmaceuticals Launches NUZYRA™ Omadacycline in the United States

2019-02-01 16:01:00 | Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635c4

2019-01-18 11:09:32 | What You Must Know About Paratek Pharmaceuticals, Inc.’s NASDAQ:PRTK Beta Value

2019-01-17 10:00:00 | Antimicrobials Working Group Announces Updates to Leadership Team

2019-01-02 16:01:00 | Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635c4

2018-12-31 16:08:01 | Penny Stocks to Buy Using Technical Analysis for January 2019

2018-12-16 02:47:12 | Arbiter Partners Capital Management’s Returns, AUM and Holdings

2018-12-06 23:50:24 | Hedge Funds Are Selling Paratek Pharmaceuticals Inc PRTK

2018-12-06 07:30:00 | Analysis: Positioning to Benefit within Paratek Pharmaceuticals, Chesapeake Utilities, Eros International, Sunoco LP, Delek Logistics Partners, and Johnson Controls International plc — Research Highlights Growth, Revenue, and Consolidated Results

2018-12-03 16:01:00 | Paratek Pharmaceuticals Files Two Patent Term Extensions in the United States; Expects NUZYRA™ Patent Protection Exclusivity Until at Least October 2030

2018-11-27 08:00:00 | Paratek Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of Omadacycline in Acute Pyelonephritis, a Common Subset of Complicated Urinary Tract Infections

2018-11-15 12:28:01 | Do Institutions Own Paratek Pharmaceuticals Inc NASDAQ:PRTK Shares?

2018-11-07 07:16:01 | Edited Transcript of PRTK earnings conference call or presentation 6-Nov-18 9:30pm GMT

2018-11-06 17:50:10 | Paratek Pharmaceuticals PRTK Reports Q3 Loss, Misses Revenue Estimates

2018-11-06 16:48:32 | Paratek: 3Q Earnings Snapshot

2018-11-06 16:02:00 | Paratek Pharmaceuticals Reports Third Quarter 2018 Financial Results

2018-11-01 16:05:00 | Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635c4

2018-10-26 16:05:00 | Paratek Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 6, 2018

2018-10-26 08:45:00 | Investor Expectations to Drive Momentum within Paratek Pharmaceuticals, Dell Technologies, Dover, Black Hills, Kinder Morgan, and Novo Nordisk A/S — Discovering Underlying Factors of Influence

2018-10-25 13:12:43 | War against the superbugs: Mass. biotechs step up to fight antibiotic resistance